HUP0302117A2 - Vakcinakompozíció - Google Patents
VakcinakompozícióInfo
- Publication number
- HUP0302117A2 HUP0302117A2 HU0302117A HUP0302117A HUP0302117A2 HU P0302117 A2 HUP0302117 A2 HU P0302117A2 HU 0302117 A HU0302117 A HU 0302117A HU P0302117 A HUP0302117 A HU P0302117A HU P0302117 A2 HUP0302117 A2 HU P0302117A2
- Authority
- HU
- Hungary
- Prior art keywords
- peptide
- amino acid
- acid residue
- antigen
- vaccine composition
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 125000000539 amino acid group Chemical group 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 150000007970 thio esters Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
A találmány legalább egy antigént és egy R1-XZXZNXZX-R2 szekvenciátmagában foglaló peptidet tartalmazó vakcinára, valamint az ismertetettpeptid alkalmazására vonatkozik legalább egy antigénnel szembeniimmunválasz fokozására szolgáló adjuváns előállítására. Aszekvenciában N jelentése 3 és 7 közötti egészszám, előnyösen 5, Xjelentése egy pozitív töltésű természetes és/vagy nem természetesaminosavmaradék, Z jelentése L, V, I, F és/vagy W aminosavmaradék, ésR1 és R2 jelentése egymástól függetlenül H, NH2, COCH3, COH képletűcsoport, legfeljebb 20 aminosavmaradékot tartalmazó peptid vagy egyreaktív peptidcsoport vagy egy peptidkapcsoló peptiddel vagy peptidnélkül; X-R2 jelentése továbbá lehet a C-terminális aminosavmaradékamidja, észtere vagy tioésztere. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0178900A AT410635B (de) | 2000-10-18 | 2000-10-18 | Vakzin-zusammensetzung |
PCT/EP2001/012041 WO2002032451A1 (en) | 2000-10-18 | 2001-10-18 | Vaccine composition comprising an antigen and a peptide having adjuvant properties |
Publications (3)
Publication Number | Publication Date |
---|---|
HUP0302117A2 true HUP0302117A2 (hu) | 2003-09-29 |
HUP0302117A3 HUP0302117A3 (en) | 2004-11-29 |
HU228382B1 HU228382B1 (en) | 2013-03-28 |
Family
ID=3688953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0302117A HU228382B1 (en) | 2000-10-18 | 2001-10-18 | Vaccine composition |
Country Status (27)
Country | Link |
---|---|
US (3) | US8361476B2 (hu) |
EP (1) | EP1326634B1 (hu) |
JP (2) | JP4227407B2 (hu) |
KR (1) | KR100598302B1 (hu) |
CN (1) | CN1248736C (hu) |
AT (2) | AT410635B (hu) |
AU (2) | AU1232602A (hu) |
BR (1) | BRPI0114994B8 (hu) |
CA (1) | CA2426490C (hu) |
CZ (1) | CZ303303B6 (hu) |
DE (1) | DE60119145T2 (hu) |
DK (1) | DK1326634T3 (hu) |
ES (1) | ES2263668T3 (hu) |
HK (1) | HK1055899A1 (hu) |
HU (1) | HU228382B1 (hu) |
IL (2) | IL154605A0 (hu) |
IS (1) | IS2608B (hu) |
MX (1) | MXPA03002828A (hu) |
NO (1) | NO330274B1 (hu) |
NZ (1) | NZ524532A (hu) |
PL (1) | PL209016B1 (hu) |
PT (1) | PT1326634E (hu) |
RU (2) | RU2328305C2 (hu) |
SI (1) | SI1326634T1 (hu) |
SK (1) | SK287618B6 (hu) |
WO (1) | WO2002032451A1 (hu) |
ZA (1) | ZA200301465B (hu) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT410635B (de) * | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
US7244438B2 (en) | 2001-01-05 | 2007-07-17 | Intercell Ag | Uses for polycationic compounds |
CA2433794A1 (en) * | 2001-01-05 | 2002-07-11 | Intercell Ag | Uses for polycationic compounds as vaccine adjuvants |
AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
EP1279404A1 (en) * | 2001-07-26 | 2003-01-29 | Istituto Superiore di Sanità | Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
EP1523557A2 (en) | 2002-07-24 | 2005-04-20 | Intercell AG | Antigens encoded by alternative reading frame from pathogenic viruses |
US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
JP2006504687A (ja) | 2002-09-13 | 2006-02-09 | インターツェル・アクチェンゲゼルシャフト | C型肝炎ウイルスペプチドの単離方法 |
US7485710B2 (en) | 2002-10-15 | 2009-02-03 | Intercell Ag | Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof |
EP2290082A1 (en) | 2003-03-04 | 2011-03-02 | Intercell AG | Streptococcus pyogenes antigens |
JP4676426B2 (ja) * | 2003-03-24 | 2011-04-27 | インターツェル・アクチェンゲゼルシャフト | 改良型ワクチン |
CN100355453C (zh) * | 2003-03-24 | 2007-12-19 | 英特塞尔股份公司 | 改进的疫苗 |
EP1608756B1 (en) | 2003-03-31 | 2009-11-18 | Intercell AG | Staphylococcus epidermidis antigens |
CA2522238A1 (en) | 2003-04-15 | 2004-10-28 | Intercell Ag | S. pneumoniae antigens |
US8076059B2 (en) * | 2003-04-16 | 2011-12-13 | Duke University | Adjuvant capable of specifically activating the adaptive immune response |
EP2275435A3 (en) | 2003-05-07 | 2011-08-31 | Intercell AG | Streptococcus agalactiae antigens I + II |
CN102304527A (zh) | 2003-05-30 | 2012-01-04 | 英特塞尔股份公司 | 肠球菌抗原 |
CA2530062A1 (en) * | 2003-07-11 | 2005-01-20 | Intercell Ag | Hcv vaccines |
US20080145383A1 (en) | 2004-03-12 | 2008-06-19 | Intercell Ag | Method for Solubilizing Peptide Mixtures |
ES2556710T3 (es) | 2004-09-24 | 2016-01-19 | Novartis Ag | Proteínas capsidiales VP1 modificadas del parvovirus B19 |
EP1931379B1 (en) | 2005-10-07 | 2013-05-29 | Health Protection Agency | Proteins with improved solubility and methods for producing and using same |
TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
EP2040745B1 (en) | 2006-06-28 | 2012-12-05 | Statens Serum Institut | Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails |
US8529911B2 (en) | 2006-07-07 | 2013-09-10 | Intercell Austria Ag | Small Streptococcus pyogenes antigens and their use |
AU2007295927A1 (en) | 2006-09-15 | 2008-03-20 | Intercell Ag | Borrelia antigens |
EP1923069A1 (en) | 2006-11-20 | 2008-05-21 | Intercell AG | Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
EP2120984A2 (en) | 2007-01-12 | 2009-11-25 | Intercell AG | Protective proteins of s. agalactiae, combinations thereof and methods of using the same |
EP2338902A1 (en) | 2007-05-02 | 2011-06-29 | Intercell AG | Klebsiella antigens |
EP2012122A1 (en) | 2007-07-06 | 2009-01-07 | Medigene AG | Mutated parvovirus structural proteins as vaccines |
US20100203083A1 (en) | 2007-05-31 | 2010-08-12 | Medigene Ag | Mutated structural protein of a parvovirus |
CA2690271A1 (en) | 2007-06-18 | 2008-12-24 | Intercell Ag | Chlamydia antigens |
WO2009115508A2 (en) | 2008-03-17 | 2009-09-24 | Intercell Ag | Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto |
JP5473899B2 (ja) | 2008-04-02 | 2014-04-16 | 国立大学法人徳島大学 | 合成ペプチドを含有する抗原薬物ビークルとこれを用いる粘膜ワクチン |
RU2010151562A (ru) | 2008-06-20 | 2012-07-27 | ВАЙЕТ ЭлЭлСи (US) | Композиции и способы применения orf1358 из бета-гемолитических стрептококковых штаммов |
US20100015171A1 (en) * | 2008-07-15 | 2010-01-21 | Statens Serum Institute | Vaccines comprising tb 10.4 |
WO2010089340A2 (en) | 2009-02-05 | 2010-08-12 | Intercell Ag | Peptides protective against e. faecalis, methods and uses relating thereto |
WO2010092176A2 (en) | 2009-02-13 | 2010-08-19 | Intercell Ag | Nontypable haemophilus influenzae antigens |
AU2010264538B2 (en) | 2009-06-22 | 2013-10-03 | Wyeth Llc | Immunogenic compositions of Staphylococcus aureus antigens |
MX2012000045A (es) | 2009-06-22 | 2012-01-30 | Wyeth Llc | Composiciones y metodos para preparar composiciones inmunogenicas de conjugado de polisacarido capsular de serotipo 5 y 8 de staphylococcus aureus. |
CN102740882A (zh) | 2009-08-27 | 2012-10-17 | 诺华有限公司 | 含有铝、寡核苷酸和聚阳离子的佐剂 |
BR112012007821A2 (pt) | 2009-10-09 | 2017-05-30 | Sanofi Sa | polipeptídeos para ligação ao "receptor de produtos finais de glicação avançada" bem como composições e métodos envolvendo os mesmos |
EP2319871A1 (en) | 2009-11-05 | 2011-05-11 | Sanofi-aventis | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |
EP2308896A1 (en) | 2009-10-09 | 2011-04-13 | Sanofi-aventis | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |
WO2011101465A1 (en) | 2010-02-19 | 2011-08-25 | Intercell Ag | Ic31 nanoparticles |
EP2547357A1 (en) | 2010-03-18 | 2013-01-23 | Novartis AG | Adjuvanted vaccines for serogroup b meningococcus |
PL3170508T3 (pl) | 2010-06-04 | 2020-04-30 | Wyeth Llc | Preparaty szczepionek |
CA2808975C (en) | 2010-08-23 | 2018-10-30 | Wyeth Llc | Stable formulations of neisseria meningitidis rlp2086 antigens |
MX350126B (es) | 2010-09-03 | 2017-08-28 | Valneva Austria Gmbh | Polipéptido aislado de las proteínas de la toxina a y la toxina b de c. difficile y usos del mismo. |
WO2012031760A1 (en) | 2010-09-08 | 2012-03-15 | Medigene Ag | Parvovirus mutated structural proteins comprising cross - protective b - cell epitopes of a hpv l2 protein as well as products and methods relating thereto |
ES2864635T3 (es) | 2010-09-10 | 2021-10-14 | Wyeth Llc | Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis |
RU2570730C2 (ru) | 2010-12-22 | 2015-12-10 | УАЙТ ЭлЭлСи | Стабильные иммуногенные композиции антигенов staphylococcus aureus |
BRPI1100857A2 (pt) * | 2011-03-18 | 2013-05-21 | Alexandre Eduardo Nowill | agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real |
ITMI20111182A1 (it) | 2011-06-28 | 2012-12-29 | Canio Buonavoglia | Vaccino per coronavirus canino |
EP2822583A2 (en) | 2012-03-09 | 2015-01-14 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
CN104428411B (zh) * | 2012-05-08 | 2018-11-23 | 健康科学西部大学 | 用于cd4+t细胞群之抗原特异性扩增的标准化离体平台 |
JP6284537B2 (ja) * | 2012-10-29 | 2018-02-28 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー | 新規粘膜アジュバントおよびデリバリーシステム |
CA2893343C (en) | 2012-12-20 | 2019-05-14 | Pfizer Inc. | Glycoconjugation process |
JP6446377B2 (ja) | 2013-03-08 | 2018-12-26 | ファイザー・インク | 免疫原性融合ポリペプチド |
US20140271723A1 (en) * | 2013-03-15 | 2014-09-18 | Saint Louis University | Adjuvant compositions and methods of using thereof |
CN105492021B (zh) | 2013-09-08 | 2018-12-04 | 辉瑞公司 | 脑膜炎奈瑟氏球菌组合物及其方法 |
WO2016130569A1 (en) | 2015-02-09 | 2016-08-18 | Mj Biologics, Inc. | A composition comprising pedv antigens and methods for making and using the composition |
MX2017010705A (es) | 2015-02-19 | 2017-12-04 | Pfizer | Composiciones de neisseria meningitidis y metodos de la misma. |
WO2016178123A1 (en) | 2015-05-04 | 2016-11-10 | Pfizer Inc. | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
CN113521007B (zh) * | 2016-07-01 | 2022-11-18 | 四川大学 | 抗菌肽衍生物在制备免疫佐剂中的用途 |
US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
IL303108B1 (en) | 2017-01-31 | 2024-03-01 | Pfizer | NEISSERIA MENINGITIDIS preparations and methods therefor |
CN107266585B (zh) * | 2017-07-13 | 2019-08-06 | 陕西科技大学 | 一种mlh融合抗菌肽及其制备方法和应用 |
EP3527223A1 (en) | 2018-02-16 | 2019-08-21 | 2A Pharma AB | Mutated parvovirus structural protein |
JP2021513840A (ja) | 2018-02-16 | 2021-06-03 | 2エー ファーマ アーベー | 自己免疫疾患の処置のためのパルボウイルス構造タンパク質 |
CN109745556A (zh) * | 2019-03-01 | 2019-05-14 | 龙阔(苏州)生物工程有限公司 | 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗 |
CN114127101A (zh) | 2019-05-20 | 2022-03-01 | 瓦尔尼瓦公司 | 用于治疗或预防呼吸道感染的亚单位疫苗 |
WO2021202456A1 (en) * | 2020-03-30 | 2021-10-07 | The Wistar Institute Of Anatomy And Biology | Synthetic soluble receptor mimics and methods of use for treatment of covid-19 |
WO2021211279A1 (en) | 2020-04-17 | 2021-10-21 | Regents Of The University Of Minnesota | SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF |
JP2023538736A (ja) | 2020-08-26 | 2023-09-11 | ファイザー・インク | B群レンサ球菌多糖-タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用 |
AU2022255923A1 (en) | 2021-04-09 | 2023-08-31 | Valneva Se | Human metapneumo virus vaccine |
WO2023083964A1 (en) | 2021-11-11 | 2023-05-19 | 2A Pharma Ab | Parvovirus structural protein against beta- and gamma-hpv |
WO2024069420A2 (en) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ271774A (en) * | 1993-08-06 | 1998-02-26 | Cytel Corp | Immunogenic peptides from the c-terminus of the mage-1 (melanoma) antigen |
JP3442824B2 (ja) * | 1993-08-30 | 2003-09-02 | 理化学研究所 | 抗菌性ペプチド類 |
JP3547504B2 (ja) * | 1994-11-01 | 2004-07-28 | 独立行政法人理化学研究所 | 新規なポリペプチド及びその用途 |
EP0991767A1 (en) * | 1997-06-11 | 2000-04-12 | Institut Pasteur | Attenuated recombinant mycobacteria useful as immunogens or as vaccine components |
ES2248914T3 (es) * | 1997-08-29 | 2006-03-16 | Corixa Corporation | Agentes bioactivos encapsulados de liberacion rapida que permiten inducir o potenciar una respuesta inmunitaria y metodos para utilizar los mismos. |
CU22700A1 (es) * | 1997-09-29 | 2001-07-31 | Ct Ingenieria Genetica Biotech | Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso |
US20020072495A1 (en) * | 2000-09-21 | 2002-06-13 | Oleg Chertov | LL-37 is an immunostimulant |
AT410635B (de) * | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
CN100355453C (zh) * | 2003-03-24 | 2007-12-19 | 英特塞尔股份公司 | 改进的疫苗 |
JP4676426B2 (ja) * | 2003-03-24 | 2011-04-27 | インターツェル・アクチェンゲゼルシャフト | 改良型ワクチン |
CA2530062A1 (en) * | 2003-07-11 | 2005-01-20 | Intercell Ag | Hcv vaccines |
-
2000
- 2000-10-18 AT AT0178900A patent/AT410635B/de not_active IP Right Cessation
-
2001
- 2001-10-18 IL IL15460501A patent/IL154605A0/xx unknown
- 2001-10-18 HU HU0302117A patent/HU228382B1/hu unknown
- 2001-10-18 CA CA2426490A patent/CA2426490C/en not_active Expired - Lifetime
- 2001-10-18 CN CNB018171168A patent/CN1248736C/zh not_active Expired - Lifetime
- 2001-10-18 RU RU2003114434/15A patent/RU2328305C2/ru active
- 2001-10-18 KR KR1020037004977A patent/KR100598302B1/ko active IP Right Grant
- 2001-10-18 CZ CZ20031299A patent/CZ303303B6/cs not_active IP Right Cessation
- 2001-10-18 SI SI200130564T patent/SI1326634T1/sl unknown
- 2001-10-18 ES ES01980496T patent/ES2263668T3/es not_active Expired - Lifetime
- 2001-10-18 SK SK575-2003A patent/SK287618B6/sk not_active IP Right Cessation
- 2001-10-18 AT AT01980496T patent/ATE324116T1/de not_active IP Right Cessation
- 2001-10-18 PL PL362966A patent/PL209016B1/pl unknown
- 2001-10-18 DE DE60119145T patent/DE60119145T2/de not_active Expired - Lifetime
- 2001-10-18 EP EP01980496A patent/EP1326634B1/en not_active Expired - Lifetime
- 2001-10-18 AU AU1232602A patent/AU1232602A/xx active Pending
- 2001-10-18 WO PCT/EP2001/012041 patent/WO2002032451A1/en active IP Right Grant
- 2001-10-18 BR BRPI0114994-6 patent/BRPI0114994B8/pt not_active IP Right Cessation
- 2001-10-18 MX MXPA03002828A patent/MXPA03002828A/es active IP Right Grant
- 2001-10-18 PT PT01980496T patent/PT1326634E/pt unknown
- 2001-10-18 JP JP2002535688A patent/JP4227407B2/ja not_active Expired - Lifetime
- 2001-10-18 NZ NZ524532A patent/NZ524532A/en not_active IP Right Cessation
- 2001-10-18 DK DK01980496T patent/DK1326634T3/da active
- 2001-10-18 US US10/399,442 patent/US8361476B2/en active Active
- 2001-10-18 AU AU2002212326A patent/AU2002212326B2/en not_active Expired
-
2003
- 2003-02-20 IS IS6722A patent/IS2608B/is unknown
- 2003-02-24 IL IL154605A patent/IL154605A/en unknown
- 2003-02-24 ZA ZA200301465A patent/ZA200301465B/en unknown
- 2003-04-08 NO NO20031595A patent/NO330274B1/no not_active IP Right Cessation
- 2003-11-12 HK HK03108189A patent/HK1055899A1/xx not_active IP Right Cessation
-
2007
- 2007-12-13 RU RU2007146372/15A patent/RU2007146372A/ru not_active Application Discontinuation
-
2008
- 2008-05-21 US US12/124,785 patent/US8900564B2/en active Active
- 2008-05-22 JP JP2008134215A patent/JP2008222721A/ja not_active Withdrawn
-
2013
- 2013-01-16 US US13/742,500 patent/US20130216583A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0302117A2 (hu) | Vakcinakompozíció | |
HUP0102900A2 (hu) | Javított szilárd fázisú peptidszintézis és a szintézisben alkalmazható anyagok | |
DE60329201D1 (de) | Substituierte wt1-peptide | |
IL122754A0 (en) | Cyclosporin derivatives their preparation and pharmaceutical compositions containing them | |
DE60144561D1 (de) | N- und/oder c-terminal mit kurzen geladenen peptidsequenzen modifizierte peptide | |
ATE280827T1 (de) | Penaeidine: antimikrobielle peptide aus krebstieren | |
DE3261304D1 (en) | Retro-inverso analogues of c-terminal penta and hexapeptides of substance p. | |
ATE284896T1 (de) | Neue antiarrythmische peptide | |
HUP0301396A2 (hu) | Integrin inhibitor hatású peptid- és peptidutánzó konjugátumok, azokat tartalmazó implantátumok és alkalmazásuk | |
HUP0203504A2 (hu) | Immunterápiás alkalmazásra szolgáló módosított peptidek és peptid-mimetikumok | |
ES2176334T3 (es) | El uso de gabapentin en el tratamiento de la ansiedad y el panico. | |
DE60018937D1 (de) | Somatostatin analoge und deren verwendung zur behandlung von krebs | |
DE602004019141D1 (de) | Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonin (ivtntt) enthaltende biologisch wirksame peptide | |
WO2001074847A3 (en) | T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer | |
DE60124299D1 (de) | Peptide aus dem b-glycoprotein des menschlichen herpesvirus-7, besonders anwendbar bei serologischen elisa-nachweisen | |
DE60022995D1 (de) | Impfstoff | |
CU22627A1 (es) | Preparado vacunal para la inmuno-castración reversible de mamíferos | |
ECSP003720A (es) | Peptidos modificados y peptidomimeticos para el uso en inmunoterapia | |
SE0002738D0 (sv) | Electric actuator | |
SE0002728D0 (sv) | New compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC9A | Change of name, address |
Owner name: INTERCELL AG, AT Free format text: FORMER OWNER(S): INTERCELL BIOMEDIZINISCHE FORSCHUNGS- UND ENTWICKLUNGS AG, AT |
|
FH91 | Appointment of a representative |
Free format text: FORMER REPRESENTATIVE(S): DR. GARDONYI ZOLTANNE, DANUBIA SZABADALMI ES VEDJEGY IRODA KFT., HU Representative=s name: DANUBIA SZABADALMI ES JOGI IRODA KFT., HU |
|
GB9A | Succession in title |
Owner name: VALNEVA AUSTRIA GMBH, AT Free format text: FORMER OWNER(S): INTERCELL BIOMEDIZINISCHE FORSCHUNGS- UND ENTWICKLUNGS AG, AT; INTERCELL AG, AT |